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Abstract
Background: Cryptococcal infection is a frequent cause of mortality in Cambodian HIV-infected patients with CD4+ count
#100 cells/ml. This study assessed the cost-effectiveness of three strategies for cryptococcosis prevention in HIV-infected
patients.
Methods: A Markov decision tree was used to compare the following strategies at the time of HIV diagnosis: no
intervention, one time systematic serum cryptococcal antigen (CRAG) screening and treatment of positive patients, and
systematic primary prophylaxis with fluconazole. The trajectory of a hypothetical cohort of HIV-infected patients with CD4+
count #100 cells/ml initiating care was simulated over a 1-year period (cotrimoxazole initiation at enrollment; antiretroviral
therapy within 3 months). Natural history and cost data (US$ 2009) were from Cambodia. Efficacy data were from
international literature.
Results: In a population in which 81% of patients had a CD4+ count #50 cells/ ml and 19% a CD4+ count between 51–100
cells/ml, the proportion alive 1 year after enrolment was 61% (cost $ 472) with no intervention, 70% (cost $ 483) with
screening, and 72% (cost $ 492) with prophylaxis. After one year of follow-up, the cost-effectiveness of screening vs. no
intervention was US$ 180/life year gained (LYG). The cost-effectiveness of prophylaxis vs. screening was $ 511/LYG. The cost-
effectiveness of prophylaxis vs. screening was estimated at $1538/LYG if the proportion of patients with CD4+ count #50
cells/ml decreased by 75%.
Conclusion: In a high endemic area of cryptococcosis and HIV infection, serum CRAG screening and prophylaxis are two
cost effective strategies to prevent AIDS associated cryptococcosis in patients with CD4+ count #100 cells/ml, at a short-
term horizon, screening being more cost-effective but less effective than prophylaxis. Systematic primary prophylaxis may
be preferred in patients with CD4+ below 50 cells/ml while systematic serum CRAG screening for early targeted treatment
may be preferred in patients with CD4+ between 51–100 cells/ml.
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Introduction
In industrialized countries, fluconazole prophylaxis is not cost-
effective to prevent primary systemic fungal infections in AIDS
(acquired immune deficiency syndrome) patients because of the
low incidence of these infections [1,2,3]. Cryptococcosis is one of
the most frequent and most serious opportunistic infections (OI) in
AIDS patients in developing countries [4,5,6]. The current global
burden of cryptococcal meningitis represents 957,900 cases each
year resulting in 624,700 deaths during the first 3 months after
infection [7]. Prevention of this opportunistic infection is a very
important public health issue in developing countries [8]. In
Cambodia, cryptococcosis was the leading cause of mortality
among hospitalized AIDS patients in the 1990s [9,10]. In four
recent studies involving severely immunosuppressed patients with
CD4+ count ,100 cells/ml initiating combination antiretroviral
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antigen (CRAG) was 20.2% (57/282) in Cambodia in 2004,
13.0% (42/336) in South Africa from 2002 to 2005, 8.8% (26/
295) in Uganda during 2004–2006 period, and 12.9% (11/85) in
Thailand [11,12,13,14]. These studies provided evidence that
systematic screening for serum CRAG was a clinically valuable
strategy for early detection and targeted pre-emptive antifungal
treatment. In addition, in another study performed in rural
Uganda, asymptomatic positive serum CRAG was found to be an
independent predictor of death during the first 12 weeks of cART
in individuals with advanced HIV disease [15]. Cambodian health
authorities currently recommend systematic primary prophylaxis
with fluconazole in HIV-infected patients with CD4+ count ,100
cells/ml (i.e. 200 mg/day orally) [16]. In 2009, the monthly cost of
generic fluconazole was US$ 1.16. The cost of one time capsular
cryptococcal polysaccharide detection was US$ 6.6. The aim of
this study was to assess the cost-effectiveness of systematic primary
prophylaxis with fluconazole (200 mg/day) or systematic serum
CRAG screening and targeted treatment of positive cases
compared to no intervention in HIV-infected patients with
CD4+ count #100 cells/ml in Cambodia.
Methods
Analytic review
First order Monte Carlo simulation of a Markov transition
model was used to project disease progression in patients with
CD4+ count #100 cells/ml presenting to care, excluding patients
with symptomatic cryptococcal meningitis. The course of the
disease was modeled for one hundred thousand hypothetical HIV-
infected individuals for 12 months after presentation to care. The
time-horizon was therefore one year. Based on the Cambodian
recommendations, it was assumed that all severely immunosup-
pressed patients initiated combination cART within three months
after detection of HIV seropositivity. Pneumocystis jirovecii prophy-
laxis with cotrimoxazole was systematically administered to all
patients. The patient trajectories with each of the following three
strategies were evaluated at the time of HIV diagnosis and clinic
enrollment: (1) no intervention in relation to cryptococcal
prevention (comparator), (2) systematic primary prophylaxis with
fluconazole 200mg/day for 6 to 12 months unless CD4+ count
increased to more than 100 cells/ml, and (3) systematic serum
CRAG screening and early targeted treatment of positive
asymptomatic patients with fluconazole 200 mg/day after system-
atic lumbar puncture for 3 months. Asymptomatic serum CRAG
was defined as positive serum CRAG detection with no pulmonary
cryptococcosis, no symptom suggestive of meningoencephalitis (i.e.
no neck stiffness, no altered mental status and no neurologic
deficit), negative CRAG detection in cerebrospinal fluid, negative
India ink staining in cerebrospinal fluid, and negative cryptococcal
cultures in cerebrospinal fluid, blood, and urine. Patients
responding to cART with a CD4+ count .100 cells/ml after 9
months of cART were dropped from intervention’s cycle, as
discontinuation of cryptococcosis prophylaxis during cART is
considered in patients with CD4+ count .100 cells/ml [17,18].
These patients remained however in the model until the end of the
simulation without the occurrence of a new cryptococcal infection
or others OI. The performance of these strategies was evaluated
using incremental cost-effectiveness analysis. Incremental cost-
effectiveness ratios were calculated as the additional cost (in US$)
of a specific strategy compared with the cost of the next less
expensive strategy, divided by the additional gain in life
expectancy (per year of life gained) for this strategy. A payer
perspective was adopted, i.e. based on the costs to the health
system. Cost and effectiveness were not discounted since the
follow-up period was less than 1 year. All costs and cost-
effectiveness ratios were expressed as dollars (2009 US$) per year
of life gained. A strategy ‘A’ was considered weakly dominated by
another strategy ‘B’ when the incremental cost-effectiveness ratio
of the strategy ‘A’ vs. the comparator (i.e. no intervention) was
higher than the incremental cost effectiveness ratio of the strategy
‘B’ vs. the strategy ‘A’. A strategy ‘A’ was considered strongly
dominated by a strategy ‘B’ when this latter strategy resulted in
higher effectiveness and a lower overall cost than the strategy ‘A’.
In addition, the performance of these strategies was estimated by
determining the number needed to test and treat (i.e., with serum
CRAG screening and early targeted treatment strategy) and the
number needed to treat (i.e., with systematic primary prophylaxis
with fluconazole) to prevent 1 death, respectively, as well as the
costs associated. To estimate the cost associated to prevent 1
death, for serum CRAG screening and early targeted treatment
strategy, we considered the cost of CRAG screening test and
fluconazole for those tested positive. For systematic primary
prophylaxis with fluconazole we considered the cost of flucona-
zole. We used our Markov transition model to project these costs.
Model structure
The model (Figure 1) characterized an individual patient’s
disease progression as a sequence of transitions from one ‘‘health
state’’ to another, each corresponding to the patient’s underlying
true health. Health states were defined by current CD4+ count
cells/ml and the efficacy of combination antiretroviral therapy.
Figure 1A describes the course of patients with or without
systematic prophylaxis, and Figure 1B with the CRAG screening
strategy. At each state, patients could develop a cryptococcal
meningitis, pulmonary cryptococcosis, or other opportunistic
infections (any OI in patients with negative serum CRAG or with
isolated positive serum CRAG). The incidence of these OIs was
stratified based on CD4+ count categories (0–50 and 51–100 cells/
ml). These OIs were assumed to lead to either death or full
recovery. The development of an OI was also assumed not to
influence the subsequent course of CD4+ count or the probability
of a subsequent OI.
Patients responding to cART virologically were considered to
have achieved successful immune reconstitution (CD4+ counts
increasing over time). The CD4+ cell gain after three months was
47cells/ml, after 6 months was 47 cells/, and after 9 months was
27cells/ml in patients responding to cART. Patients non
responding to cART were considered to decline their CD4+
count during follow-up [19,20]. The duration of each cycle was 3
months. The non-responder status to cART was assumed to be
constant during the patient’s follow-up. The initial CD4+ count
and non-responder status to cART of each patient were randomly
selected from given distributions. The sequence of clinical
trajectories for a given patient until death or end of simulation
was fully determined by a set of estimated probabilities.
Baseline characteristics and transition probabilities
(Table 1)
CD4+ distributions in HIV-infected patients seen for the first
time were from two highly active antiretroviral therapy access
program in Phnom Penh (Prea Bat Norodom Sihanouk Hospital -
program supported by Me ´decins Sans Frontie `res, and Kosamak
Hospital – program supported by Me ´decins Du Monde) [11]: 81%
of patients had a CD4+ count #50 cells/ ml and 19% a CD4 cell
count between 51–100 cells/ml. The probability of positive serum
CRAG and mortality due to cryptococcal infection were from
Micol et al. study in antiretroviral therapy access programs in
AIDS-Cryptococcosis Prevention
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System (CALAS; Meridian Bioscience Europe, Nice, France). The
sensitivity and specificity of the test (used in a laboratory) are 99%
and 97%, respectively [21]. All patients’ data routinely entered in
Fuchia v1.5 (Epicentre – MSF) from the Me ´decins Sans Frontie `res
Cambodian cohort in 2004–2005 were used to calculate the risk of
Table 1. Estimates of the probabilities of events.
Variable probability CD4+ cells/ml % Reference
[0–50] [51–100]
CD4+ distribution in patients attending for the first time the cART
program
81 19 [11]
Probability of cART immunological efficacy after 1 year on cART 86.0 86.0 MSF database, [19]
Probability CD4+ cell increase above 100 cells/m after 6 months of
successful cART
46.0 46.0 [22]
Asymptomatic positive serum CRAG at screening 14.3 4.3 [11]
Probability of CM MSFdatabase, [11]
Without fluconazole prophylaxis 15.4 9.1
With fluconazole primary prophylaxis 1.0 1.0
With fluconazole secondary prophylaxis 15.0 10.0
With negative serum CRAG without fluconazole primary prophylaxis 0.6 0.0
With positive serum CRAG without fluconazole primary prophylaxis 48.3 0.0
Probability of pulmonary cryptococcosis MSF database, [11]
Without fluconazole prophylaxis 3.1 1.8
With fluconazole primary prophylaxis 0.1 0.1
With fluconazole secondary prophylaxis 10.0 5.0
With negative serum CRAG without fluconazole primary prophylaxis 0.000 0.000
With positive serum CRAG without fluconazole primary prophylaxis 39.0 69.8
Probability of OI other than cryptococcal infection MSF database
For patients with negative serum CRAG 0.540 0.395
For patients with isolated positive serum CRAG 0.540 0.395
Probability of death MSF database, [11]
In patients with CM 0.53 0.53
In patients with pulmonary cryptococcosis 0.200 0.200
In patients with another OI 0.200 0.200
CM, cryptococcal meningitis; OI, opportunistic infections; cART, combination antiretroviral therapy; CRAG, cryptococcal antigen.
doi:10.1371/journal.pone.0013856.t001
Figure 1. Model structure for no intervention or primary prophylaxis intervention (A), and CRAG screening intervention for
treatment of positive cases (B). The probabilities of transition were stratified according to CD4+ count categories (0–50 and 51–100 cells/ml). At
the end of one cycle (i.e., after 3 months), patient was back to start of cycle state within the same CD4 cell count strata or a higher CD4 cell count
based on cART efficacy or was remaining alive in the model (without occurrence of new OI) because of death or CD4 cell count .100 cells/ml thanks
to cART efficacy. Pulm. Crypto.: pulmonary cryptococcosis; CM: cryptococcal meningitis; OI: opportunistic infections other than cryptococcosis;
+: positive serum CRAG screening; 2: negative serum CRAG screening; Isolated CrAG+: Asymptomatic positive serum CRAG. Non-response to cART
was included in the transition probabilities.
doi:10.1371/journal.pone.0013856.g001
AIDS-Cryptococcosis Prevention
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probabilities were stratified on two categories of CD4+ count (#50
cells/ml versus 51–100 cells/ml) and were determined for three
months (probability of cryptococcal meningitis or pulmonary
cryptococcosis with or without fluconazole prophylaxis, probabil-
ity of others OI, probability of death). We used data from another
study performed by our group in Cambodia to estimate the CD4+
count increase in patients on efficacious cART (i.e. to estimate the
time that the patients remains below 100 CD4+ cells/ml) [22]. In
the latter study, we showed that in patients with a median (Q1–
Q3) of CD4+ count at baseline at 20 cells/ml (6–78), the CD4+
count increased after cART initiation to reach median levels of
130 cells cells/ml (IQR, 87–189) at 6 months and 189 cells/ml
(IQR, 135–250) at 12 months. In other studies, ART efficacy was
estimated at 86% after one year on cART. In patients responding
to cART the CD4+ cell gain was 47cells/ml after three months, 94
cells//ml after 6 months, and 121 cells/ml after 9 months. Patients
non responding to cART were considered to decline their CD4+
count by 18.8 CD4+ cells/ml every three months [19,20]. More
details about the model are available in the technical appendix
S1.
Costs (Table 2)
Costs included direct medical costs were expressed in 2009 US$.
Drugs costs were from MSF cART access programs. Cotrimox-
azole Pneumocystis jirovecii prophylaxis cost was 0.30 $/month,
fluconazole prophylaxis cost 1.16 $/month, and cART treatment
30.5 $/month. Test costs and in particular CRAG screening test
(6.6 $) costs were from the manufacturer (CALAS; Meridian
Bioscience Europe, Nice, France) and did include the time of
human resource to perform the test. To estimate costs related to
cryptococosis disease and other opportunistic disease treatment
and care, we considered inpatients and outpatients stays,
treatment and test costs. Inpatient costs were from Me ´decins Sans
Frontie `res, outpatients costs were from Me ´decins Du Monde.
Cryptococcal meningitis (i.e.; treated with amphotericin B for 2
weeks and fluconazole 400mg/day for 8 to 10 weeks) and others
OI treatment was estimated at 62.6 $/month. Patients with
pulmonary cryptococcosis (mainly a severe pneumonia) received
the same treatment as the patients with cryptococcal meningitis
[17].
Sensitivity analysis
One-way sensitivity analyses were performed by varying key
parameters (proportions of patients with CD4+ count #50 cells/
ml, cost of fluconazole prophylaxis, cost of CRAG screening, and
mortality rate due to cryptococcal meningitis) over a wide range of
reasonable values to evaluate the impact of data uncertainties and
to determine the robustness of the overall conclusions.
Analyses were performed with TreeAge ProTM 2006 (Williams-
town, MA, USA). This study was approved by the National Ethics
Committee for Health Research of the Cambodia Ministry of
Health.
Results
Baseline analysis
After one year of follow-up, primary prophylaxis by fluconazole
or systematic CRAG screening and treatment of positive cases
were more effective (probability of being alive at twelve
months=72% and 70% respectively) and more expensive (twelve
months cost=492 $ and 483 $ respectively) than the ‘‘no
intervention’’ strategy (61%, and 472 US$)( Table 3). Although
the ‘‘prophylaxis strategy’’ was more expensive than the
‘‘screening strategy’’ ($ 492 vs. $ 483 over a period of twelve
months), it was also more effective (probability of being alive at
twelve months=72% vs. 70%). The cost-effectiveness of ‘‘screen-
ing strategy’’ (=180 $/ life year gained [LYG] vs. no intervention)
was lower than the cost-effectiveness of primary prophylaxis (511
$/LYG compared to screening) (Table 3). Compared to ‘‘no
intervention’’ strategy, to prevent 1 death, 10.8 persons needed to
undergo CRAG screening and treatment of positive cases, and 8.9
persons needed to be treated by fluconazole prophylaxis,
respectively. On the basis of the current CRAG test ($6.6/test)
and fluconazole prophylaxis cost ($3.47/3 months) this translates
into $77 to save 1 life with serum CRAG screening and early
targeted treatment strategy and $102 to save 1 life with fluconazole
prophylaxis strategy.
Sensitivity analysis
One-way sensitivity analysis was initially performed on the
proportion of patients with CD4+ count #50 cells/ml attending
for the first time the cART access program (Table 4). Results
were sensitive to variations in the proportion of patients with a
CD4+ count #50 cells/ml at enrollment. If the proportion of
patients attending the HIV clinic for the first time with CD4+
count #50 cells/ml increased by 25% to 97.3% of the clinic
population (vs. 81% in the basecase analysis), the incremental
cost-effectiveness ratio of both interventional strategies decreased
and especially the incremental cost-effectiveness ratio of prophy-
laxis vs. screening decreased to 478 $/LYG. If this proportion
decreased by 50% to 40.5%, the incremental cost-effectiveness
ratio of prophylaxis vs. screening increased to 733 $/LYG.
Finally if this proportion decreased by 75% to 20.3%, the
incremental cost-effectiveness ratio of prophylaxis vs. screening
increased to 1538 $/LYG. Reducing the cost of fluconazole (from
3.47 $ to 1.74 for three months) reduced fluconazole prophylaxis
cost-effectiveness ratio (from 511 to 256 $/LYG respectively)
(Table 5). When the cost of fluconazole is free (i.e. cost of
fluconazole=0 $) such as in the Pfizer Diflucan Partnership
Program [23], screening strategy is weakly dominated (i.e.
screening presented a higher incremental cost-effectiveness ratio
than prophylaxis that is more effective) and the incremental cost-
effectiveness ratio of prophylaxis vs. no intervention decreased to
141 $/LYG. Reducing the CRAG screening test cost (from 6.6$
to 3.3, or 1.7 $) decreased the incremental cost-effectiveness ratio
of screening from 180, to 137, and 116 $/LYG respectively. A
reduction of the mortality rate due to cryptococcal meningitis also
did not inverse the results but favored the incremental cost-
effectiveness ratio of screening.
Table 2. Estimates of the costs.
Costs in 2009 US$/3 months (MSF and MDM databases)
Cotrimoxazole Pneumocystis jirovecii prophylaxis 0.89
Fluconazole prophylaxis 3.47
cART 91.5
CM/Pulmonary cryptococcosis treatment and care 187.9
Other opportunistic infections treatment and care 187.9
CRAG screening test (cost per test) 6.63
cART, combination antiretroviral therapy; CM, cryptococcal meningitis;
CRAG, cryptococcal antigen.
doi:10.1371/journal.pone.0013856.t002
AIDS-Cryptococcosis Prevention
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This is the first study assessing the cost-effectiveness of three
alternative prevention strategies of cryptococcal infection in HIV-
infected patients. Cryptococcal opportunistic infection is highly
endemic in Cambodia (estimated prevalence in HIV-infected
patients with CD4+ count #100 cells/ml of 20.6% (58/282) in
2004 [11]) and represents more generally a significant public
health burden in South East Asian AIDS patients [4,5,9,24,25].
The results of the present study suggest that, at a short term
horizon of one year, the systematic CRAG screening (for targeted
treatment of positive cases) in patients with CD4+ cell counts
,100 cells/ml presenting to care in Cambodia, is more cost
effective for cryptococcosis prevention compared to the systematic
primary prophylaxis strategy. They also illustrate however that
systematic primary prophylaxis strategy is more effective than
systematic CRAG screening and associated with an acceptable
cost-effectiveness ratio (US$ 511/LYG). Although there is no
clearly defined threshold below which any health intervention can
be considered to be cost-effective, the guidelines of the WHO
Commission on Macroeconomics and Health can be used to
establish the comparative value of alternative interventions in a
given country, taking into account its ability to pay for goods and
services [26]. According to these guidelines, a strategy is cost-
effective if the incremental cost-effectiveness ratio is below 36the
annual per capita Gross Domestic Product (GDP) and very cost-
effective if the incremental cost-effectiveness ratio is below 16the
annual per capita GDP. The Cambodian GDP was US$ 650
in 2008 (http://www.imf.org/external/pubs/ft/weo/2007/02/
weodata/index.aspx). Because the incremental cost-effectiveness
ratio of systematic primary prophylaxis strategy vs. CRAG screening
($ 511) is less than the Cambodian GDP, this strategy could be
considered as a very cost effective strategy to prevent AIDS associated
cryptococcosis in Cambodia.
The cost-effectiveness of strategies to prevent AIDS associated
cryptococcosis in Cambodia estimated in our study are compa-
rable to the cost-effectiveness of other strategies implemented in
developing countries to prevent opportunistic infections occur-
rence in HIV-infected patients although we recognize the need for
caution in directly comparing results of cost-effectiveness analysis
Table 3. Cost-Effectiveness of systematic fluconazole primary prophylaxis and serum cryptococcal antigen screening.
Strategy Cost ($) Effectiveness* (in year) 1 year survival (%) Cost per LYG ($/LYG) ICER ($ incr./LYG)
No intervention 472 0.741 61 636 Reference
CRAG screening+targeted therapy 483 0.803 70 601 180.0**
Fluconazole prophylaxis 492 0.822 72 599 511.0***
$: costs in 2009 US$, LYG, life year gained; CE, cost-effectiveness; ICER, Incremental cost-effectiveness ratio.
*Effectiveness=mean life expectancy one year after HIV diagnosis and clinic enrollment.
**ICER of CRAG screening vs. no intervention.
***ICER of prophylaxis vs. CRAG screening.
doi:10.1371/journal.pone.0013856.t003
Table 4. Sensitivity analyses: impact on the results of varying the proportion of patients with CD4+ count #50 cells/ml.
Cost (2009 $) Effectiveness* in years Incremental CE ratio ($/LYG)**
Increasing the proportion of patients with CD4+ count #50 cells/ml by 20% (i.e. 0.9732)
No intervention 485 0.727
Serum CRAG screening 495 0.788 170
Fluconazole prophylaxis 506 0.811 478
Reducing the proportion of patients with CD4+ count #50 cells/ml by 25% (i.e. 60.75%)***
No intervention 456 0.761
Serum CRAG screening 468 0.824 198
Fluconazole prophylaxis 474 0.835 550
Reducing the proportion of patients with CD4+ count #50 cells/ml by 50% (i.e. 40.5%)
No intervention 439 0.783
Serum CRAG screening 450 0.838 207
Fluconazole prophylaxis 455 0.844 733
Reducing the proportion of patients with CD4+ count #50 cells/ml by 75% (i.e. 20.25%)
No intervention 424 0.801
Serum CRAG screening 437 0.858 214
Fluconazole prophylaxis 439 0.859 1538
$: costs in 2009 US$, CRAG, cryptococcal antigen.
*Effectiveness=mean life expectancy one year after HIV diagnosis and clinic enrollment.
**US$ per year of life gained.
***The proportion of patients attending the HIV clinic for the first time with CD4+ count #50 cells/ml is 81.2% as baseline. Thus the reduction of this latter proportion by
25% decreased this proportion to 60.75%.
doi:10.1371/journal.pone.0013856.t004
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the time horizon of studies. For example, the cost-effectiveness of
co-trimoxazole prophylaxis for persons at early stages of HIV
infection (WHO stage . or =2) compared to no prophylaxis has
been evaluated at 150 $/LYG in Co ˆte d’Ivoire [27] The cost-
effectiveness of isoniazid preventive therapy in newly HIV-infected
patients with positive tuberculin skin test has been evaluated at 102
$/QALY gained in counseling and testing centers in Kampala,
Uganda [28]. In the same study, the cost-effectiveness of isoniazid
preventive therapy in all newly HIV-infected patients regardless to
positive tuberculin skin test has been evaluated at 106US$/QALY
gained compared to the targeted testing strategy. Moreover, as far
as cryptococcal infection prevention in HIV-infected patients is
considered a recent study in Uganda showed that initial CRAG
screening prior to starting ART in patients with CD4+ count
#100 cells/ml is cost-effective; the number of patients needed to
test and treat with CRAG screening and fluconazole to save 1 life
was estimated 15.9 and the costs at $266 [13]. Systematic primary
prophylaxis strategy was not evaluated in this study.
In this Cambodian analysis we found that a decrease in the
proportion of patients with CD4+ count #50 cells/ml significantly
impacted the incremental cost-effectiveness ratio of screening and
prophylaxis strategies. When this latter proportion is about 20.3%,
the prophylaxis strategy is a less cost effective strategy (the
incremental cost-effectiveness ratio of prophylaxis vs. screening is
around 1500 $/LYG). In contrast when this proportion is
increased, the prophylaxis strategy becomes more cost-effective.
From these data, one may hypothesize that in patients with CD4
count #50 cells/ml and a higher cryptococcosis incidence, the
prophylaxis strategy in addition to being a more effective strategy
for cryptococcal infection prevention is probably associated with
an acceptable cost-effective ratio. In contrast, in patients with CD4
cell count between 51 and 100 cells/ml, prophylaxis strategy is
associated with higher cost-effectiveness ratio and screening
strategy may be the preferred strategy. One should consider that
in addition cryptococcosis systematic screening is clinically
valuable for the diagnosis of isolated positive CRAG in serum
and asymptomatic cryptococcal meningitis [11,12,13,14]. In the
Cambodian study, of the 59 patients with cryptococcal infection,
17 (28.8%) would not have been diagnosed on the day of
consultation without the agglutination test performed on serum.
These patients received appropriate treatment for asymptomatic
isolated positive CRAG or asymptomatic cryptococcal meningitis,
which decreased either the risk of developing subsequent
cryptococcal meningitis or the risk of mortality. In the absence
of treatment these patients may further more develop cryptococcal
immune reconstitution inflammatory syndrome [29] that is issue in
South East Asia [30].
Results of the present study are based on transition probabilities
drawn from real-life data and are applicable to the setting from
which the results were derived. They present in addition several
limitations and several points should be discussed before they can
be used in the field of decision-making. We used a simulation
model that combines input data from multiple sources and relies
on several assumptions, although most of input data were from
Cambodia. We measured resource use and effects of evaluated
strategies over a 1-year-period after the time of HIV diagnosis and
clinic enrollment (i.e.; the time horizon of the study one year).
Table 5. Sensitivity analyses: impact on the results of varying the cost of fluconazole, the cost of CRAG screening test, and the
cryptococcal meningitis mortality rate.
Cost (2009 $) Effectiveness* in years Incremental CE ratio ($/LYG)**
Reducing the cost of fluconazole by 50% (i.e. $ 1.74)
No intervention 470 0.741
Serum CRAG screening 482 0.803 190
Fluconazole prophylaxis 487 0.821 256
Reducing the cost of fluconazole by 100% (i.e. $ 0.0)
No intervention 469 0.741
Serum CRAG screening 480 0.803 Weakly dominated
Fluconazole prophylaxis 480 0.821 141.0 (vs. no intervention)
Reducing the cost of CRAG screening test by 50% (i.e. $ 3.315)
No intervention 472 0.741
Serum CRAG screening 480 0.803 137
Fluconazole prophylaxis 492 0.821 678
Reducing the cost of CRAG screening test by 75% (i.e. $ 1.6575)
No intervention 472 0.741
Serum CRAG screening 479 0.803 116
Fluconazole prophylaxis 492 0.821 750
Reducing the cryptococcal meningitis mortality rate by 25% (i.e. 39.75%)
No intervention 487 0.7683
Serum CRAG screening 489 0.8111 44
Fluconazole prophylaxis 495 0.8250 446
$: costs in 2009 US$; CRAG, cryptococcal antigen;
*Effectiveness=mean life expectancy one year after HIV diagnosis and clinic enrollment;
**US$ per year of life gained.
doi:10.1371/journal.pone.0013856.t005
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term chronic disease associated with a life expectancy increasing
over time [31]. Long-term cost-effectiveness of cryptococcal
infection prevention strategies may be different than results that
we have reported in this manuscript. Nevertheless, first we believe
that evaluating the cost-effectiveness of cryptococcal infection
prevention in the short-term is by itself a valuable information for
clinicians and policy makers. Moreover, because morbidities and
mortality related to cryptococcal infections primarily occur during
the first year following HIV diagnosis, estimating consequences of
prevention strategies initiated at HIV care over a 1-year-period
allow us to capture important effects related to these strategies. In
this analysis, we were not able to estimate the incidence of each
specific OI because of lack of available data and thus estimated the
incidence of OIs overall. Adverse effects of drugs were not taken
into account, and could be an argument in favor of the screening
strategy. The exposure of cryptococcosis-free subjects to unnec-
essary treatment could lead to unnecessary adverse effects
including ecological impact and costs. Indeed the primary
prophylaxis for cryptococcal infection impact the occurrence of
fluconazole resistance on Candida species [32]. Furthermore,
fluconazole might have an ecological impact with the emergence
of less susceptible Cryptococcus and Candida isolates. This has
been well described by Bicanic et al. among symptomatic relapse of
HIV-associated cryptococcal meningitis after initial fluconazole
monotherapy [33]. Treatment adherence was assumed to be
perfect, which could affect the results of both strategies, as
incomplete adherence could affect the efficacy of treatment.
Finally, disability weighting associated with years of life lived
within categories defined in our model was not available. As such,
we expressed our results in cost per year of life gained.
This study suggests that systematic serum CRAG screening and
systematic primary prophylaxis strategies in patients with CD4+
count #100 cells/ml are very cost-effective strategies for the
management of opportunistic cryptococcosis in newly diagnosed
HIV-infected patients in Cambodia in 2009, although systematic
primary prophylaxis was found to be more effective. Cost-
effectiveness ratios associated with these strategies are in line with
the cost-effectiveness of other strategies already implemented to
prevent OI occurrence in HIV-infected patients in developing
countries. Based on the results of this study one may consider that
at the enrolment of patients in antiretroviral access program in
Cambodia, patients should receive systematic fluconazole prophy-
laxis when CD4+ count is below 50 cells/ml and rather a
systematic serum CRAG screening (for targeted treatment of
positive cases) may be considered when CD4+ count is between
51–100 cells/ml.
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